A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients

Hidehiko Ishioka, Motowo Mizuno, Susumu Take, Kuniharu Ishiki, Yasuhiro Nagahara, Tomowo Yoshida, Hiroyuki Okada, Kenji Yokota, Keiji Oguma

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background/Aims: In Helicobacter pylori eradication therapy, using a proton pump inhibitor plus amoxicillin and clarithromycin (PPI/AC regimen), the impact of the clarithromycin dose and smoking on efficacy is conflicting. Here, we compared the efficacy of 400 and 800 mg of clarithromycin in the regimen in relation to smoking in patients with peptic ulcer disease. Methods: We studied 601 H. pylori-positive patients with peptic ulcer disease who had received amoxicillin 750 mg and clarithromycin 200 or 400 mg together with lansoprazole 30 mg b.i.d. Results: 305 patients were treated with a regimen containing 400 mg of clarithromycin (C400 group), and 296 patients with a regimen containing 800 mg (C800 group). Overall cure rates between the two groups were not significantly different, but the cure rate in the C800 group was significantly better than that in the C400 group among patients infected with clarithromycin-sensitive strains (p = 0.03). This difference could be attributed to differences among smokers versus non-smokers: the cure rate among smokers in the C800 group (91.0%) was better than that in the C400 group (80.0%, p = 0.003). Conclusions: 800 mg of clarithromycin is recommended in the PPI/AC regimen for patients who smoke and are infected with clarithromycin-sensitive H. pylori.

Original languageEnglish
Pages (from-to)63-68
Number of pages6
JournalDigestion
Volume75
Issue number2-3
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Clarithromycin
Helicobacter Infections
Peptic Ulcer
Helicobacter pylori
Smoking
Amoxicillin
Therapeutics
Lansoprazole
Proton Pump Inhibitors
Smoke

Keywords

  • Clarithromycin dose
  • Helicobacter pylori
  • Smoking
  • Triple therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. / Ishioka, Hidehiko; Mizuno, Motowo; Take, Susumu; Ishiki, Kuniharu; Nagahara, Yasuhiro; Yoshida, Tomowo; Okada, Hiroyuki; Yokota, Kenji; Oguma, Keiji.

In: Digestion, Vol. 75, No. 2-3, 08.2007, p. 63-68.

Research output: Contribution to journalArticle

Ishioka, Hidehiko ; Mizuno, Motowo ; Take, Susumu ; Ishiki, Kuniharu ; Nagahara, Yasuhiro ; Yoshida, Tomowo ; Okada, Hiroyuki ; Yokota, Kenji ; Oguma, Keiji. / A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. In: Digestion. 2007 ; Vol. 75, No. 2-3. pp. 63-68.
@article{d534dbc04ffe409688c4014fddf739d1,
title = "A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients",
abstract = "Background/Aims: In Helicobacter pylori eradication therapy, using a proton pump inhibitor plus amoxicillin and clarithromycin (PPI/AC regimen), the impact of the clarithromycin dose and smoking on efficacy is conflicting. Here, we compared the efficacy of 400 and 800 mg of clarithromycin in the regimen in relation to smoking in patients with peptic ulcer disease. Methods: We studied 601 H. pylori-positive patients with peptic ulcer disease who had received amoxicillin 750 mg and clarithromycin 200 or 400 mg together with lansoprazole 30 mg b.i.d. Results: 305 patients were treated with a regimen containing 400 mg of clarithromycin (C400 group), and 296 patients with a regimen containing 800 mg (C800 group). Overall cure rates between the two groups were not significantly different, but the cure rate in the C800 group was significantly better than that in the C400 group among patients infected with clarithromycin-sensitive strains (p = 0.03). This difference could be attributed to differences among smokers versus non-smokers: the cure rate among smokers in the C800 group (91.0{\%}) was better than that in the C400 group (80.0{\%}, p = 0.003). Conclusions: 800 mg of clarithromycin is recommended in the PPI/AC regimen for patients who smoke and are infected with clarithromycin-sensitive H. pylori.",
keywords = "Clarithromycin dose, Helicobacter pylori, Smoking, Triple therapy",
author = "Hidehiko Ishioka and Motowo Mizuno and Susumu Take and Kuniharu Ishiki and Yasuhiro Nagahara and Tomowo Yoshida and Hiroyuki Okada and Kenji Yokota and Keiji Oguma",
year = "2007",
month = "8",
doi = "10.1159/000102301",
language = "English",
volume = "75",
pages = "63--68",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients

AU - Ishioka, Hidehiko

AU - Mizuno, Motowo

AU - Take, Susumu

AU - Ishiki, Kuniharu

AU - Nagahara, Yasuhiro

AU - Yoshida, Tomowo

AU - Okada, Hiroyuki

AU - Yokota, Kenji

AU - Oguma, Keiji

PY - 2007/8

Y1 - 2007/8

N2 - Background/Aims: In Helicobacter pylori eradication therapy, using a proton pump inhibitor plus amoxicillin and clarithromycin (PPI/AC regimen), the impact of the clarithromycin dose and smoking on efficacy is conflicting. Here, we compared the efficacy of 400 and 800 mg of clarithromycin in the regimen in relation to smoking in patients with peptic ulcer disease. Methods: We studied 601 H. pylori-positive patients with peptic ulcer disease who had received amoxicillin 750 mg and clarithromycin 200 or 400 mg together with lansoprazole 30 mg b.i.d. Results: 305 patients were treated with a regimen containing 400 mg of clarithromycin (C400 group), and 296 patients with a regimen containing 800 mg (C800 group). Overall cure rates between the two groups were not significantly different, but the cure rate in the C800 group was significantly better than that in the C400 group among patients infected with clarithromycin-sensitive strains (p = 0.03). This difference could be attributed to differences among smokers versus non-smokers: the cure rate among smokers in the C800 group (91.0%) was better than that in the C400 group (80.0%, p = 0.003). Conclusions: 800 mg of clarithromycin is recommended in the PPI/AC regimen for patients who smoke and are infected with clarithromycin-sensitive H. pylori.

AB - Background/Aims: In Helicobacter pylori eradication therapy, using a proton pump inhibitor plus amoxicillin and clarithromycin (PPI/AC regimen), the impact of the clarithromycin dose and smoking on efficacy is conflicting. Here, we compared the efficacy of 400 and 800 mg of clarithromycin in the regimen in relation to smoking in patients with peptic ulcer disease. Methods: We studied 601 H. pylori-positive patients with peptic ulcer disease who had received amoxicillin 750 mg and clarithromycin 200 or 400 mg together with lansoprazole 30 mg b.i.d. Results: 305 patients were treated with a regimen containing 400 mg of clarithromycin (C400 group), and 296 patients with a regimen containing 800 mg (C800 group). Overall cure rates between the two groups were not significantly different, but the cure rate in the C800 group was significantly better than that in the C400 group among patients infected with clarithromycin-sensitive strains (p = 0.03). This difference could be attributed to differences among smokers versus non-smokers: the cure rate among smokers in the C800 group (91.0%) was better than that in the C400 group (80.0%, p = 0.003). Conclusions: 800 mg of clarithromycin is recommended in the PPI/AC regimen for patients who smoke and are infected with clarithromycin-sensitive H. pylori.

KW - Clarithromycin dose

KW - Helicobacter pylori

KW - Smoking

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=34548295218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548295218&partnerID=8YFLogxK

U2 - 10.1159/000102301

DO - 10.1159/000102301

M3 - Article

C2 - 17476101

AN - SCOPUS:34548295218

VL - 75

SP - 63

EP - 68

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 2-3

ER -